SiDx Appoints Dr. Caroline Popper to Board of Directors
Heritage Partners is honored to have played a role as the consultants to SiDx in the recruiting of Caroline Popper as a Board Member. SiDx is a Seattle based diagnostics firm pioneering a new rapid diagnostic platform based on silicon photonics.
Dr. Popper is President of Popper and Company, a consultancy she co-founded in 2003 offering strategy and transaction advisory services to healthcare and life science companies. She was a founder of Diversigen, a science-driven microbiome analysis company recently acquired by OraSure Technologies. She is currently an Advisory Board member to the Johns Hopkins Bloomberg School of Public Health and to Riverside Partners, a private equity firm for healthcare and technology companies. In addition to SiDx, Dr. Popper also serves as a Board Member to Avance Clinical, Agilex BioLabs, and LBT Innovations.
Dr. Popper’s early career included leadership roles with MDS Proteomics and BDGene, the molecular diagnostics division of Becton Dickinson. She earned a medical degree from University of Witwatersrand and a MPH from The Johns Hopkins University.
The recruiting effort was led by Alan Thomas, Partner with Heritage Partners.
Heritage Partners is a senior level retained executive search firm working in the life sciences and digital healthcare vertical. The firm’s strength is in providing executive leadership to emerging clients at the interface of science and business.
Apexigen Appoints Dr. Thomas Jahn as Vice President, Clinical Development
Heritage Partners is honored to have played a role as the consultants to Apexigen in the recruiting of Dr. Thomas Jahn to Apexigen in the role of Vice President, Clinical Development.
Dr. Jahn previously held the position of Vice President, Clinical Development at RAPT Therapeutics, where he oversaw the clinical development of FLX475. Prior to RAPT, Dr. Jahn served as Vice President, Clinical Science at Kartos, where he oversaw the clinical development of KRT-232. At Abbvie, he led the development of venetoclax (VENCLEXTA®) for the treatment of MDS and coordinated that development with Genentech/Roche, and he was instrumental in the development of navitoclax for the treatment of myelofibrosis. While at Gilead Sciences, Dr. Jahn was the clinical lead on two pivotal Phase 3 studies leading to the approval of idelalisib (ZYDELIGÒ) combination therapy in CLL.
His early career included appointments as a research physician at the Stanford University School of Medicine and at the Keck School of Medicine at the University of Southern California. His early research interests spanned hematology/oncology, stem cell transplantation, clinical immunology and translational science.
“I am very excited about the promising results to date with APX005M combination treatment in patients with high unmet medical needs in multiple solid tumor indications and settings,” said Dr. Jahn. “I am grateful for the opportunity to contribute to the further clinical development of APX005M as well as to advance Apexigen’s pipeline programs.”
Veteran life sciences recruiter Tig Conger managed the project for Heritage Partners. “Apexigen has one of the most robust technology platforms in the immuno-oncology vertical, and Dr. Jahn is a thought leader in both the underlying science and the clinical utility of therapeutic antibodies. He is a Physician/Scientist of remarkable depth and breadth, and a rising prominance in the field,” said Conger.
Heritage Partners is a senior level retained executive search firm working in the life sciences and digital healthcare vertical. The firm’s strength is in providing executive leadership to emerging clients at the interface of science and business.
CAMBRIDGE, MA
